Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Natera, Inc. reported an insider equity award for its CEO and President, Steven Leonard Chapman. On January 14, 2026, 152,718 shares of Natera common stock were acquired at a price of $0 per share through the vesting of a performance-based Restricted Stock Unit (RSU) award. This award was originally granted on January 27, 2023 and vests in tranches when a mix of time-based and business performance milestones are achieved.
Following this vesting event, Chapman directly beneficially owned 289,286 shares of Natera common stock. The transaction reflects equity compensation tied to meeting a certified performance threshold rather than an open-market purchase.
Natera, Inc. reported an insider equity award event for John Fesko, its President and Chief Business Officer. On January 14, 2026, he acquired 44,698 shares of Natera common stock at $0 per share, reported as an acquisition of non-derivative securities. This came from a performance-based restricted stock unit (RSU) award granted on January 27, 2023, which vests in tranches when time-based and business performance milestones are achieved. The certification of one such performance milestone triggered this vesting. Following this transaction, Fesko beneficially owns 195,397 shares of Natera common stock directly.
Natera, Inc. executive Solomon Moshkevich reported an equity award tied to performance goals. On January 14, 2026, 44,698 shares of Natera common stock were acquired at $0 per share when a performance threshold under a previously granted performance-based restricted stock unit (RSU) award was certified.
The RSU grant, originally awarded on January 27, 2023, vests in tranches upon achieving milestones based on time and business performance criteria. Following this vesting event, Moshkevich directly beneficially owns 168,197 shares of Natera common stock.
Natera, Inc.’s Secretary and Chief Legal Officer, Daniel Rabinowitz, reported the vesting of 37,248 shares of Common Stock on January 14, 2026. These shares came from a performance-based Restricted Stock Unit award granted on January 27, 2023, which vests in tranches when time and business performance milestones are achieved.
After this zero-cost acquisition, Rabinowitz beneficially owns 245,849 shares of Natera Common Stock directly. The vesting followed certification that a specified performance threshold under the RSUs had been met.
Natera, Inc. director and co-founder Sheena Jonathan reported the vesting of 7,450 shares of Common Stock on January 14, 2026. These shares vested under a performance-based Restricted Stock Unit award granted on January 27, 2023, after a milestone tied to time and business performance criteria was certified. Following this vesting, she holds 270,031 shares of Common Stock directly. She also has indirect beneficial ownership of 22,532 shares held by Caraluna 1 Trust and 22,532 shares held by Caraluna 2 Trust.
Natera, Inc. furnished a current report stating that on January 11, 2026, it issued a press release with preliminary financial results for its fourth quarter and full fiscal year ended December 31, 2025. The press release is included as Exhibit 99.1, giving investors an early look at the company’s recent performance ahead of full audited results. The company specifies that this information, including Exhibit 99.1, is being furnished rather than filed, which means it is not subject to certain liability provisions under the securities laws or automatically incorporated into other SEC filings unless expressly referenced.
A Natera, Inc. director and co‑founder reported recent changes in their holdings of the company’s common stock. On December 15, 2025, they donated 1,060 shares as a charitable contribution at a reported price of $0.
On December 17, 2025, they sold 1,592, 1,348 and 130 shares in separate transactions at weighted average prices of $226.5404, $227.4355 and $228.2831 per share, effected under a Rule 10b5‑1 trading plan adopted on December 11, 2024. After these transactions, the reporting person directly beneficially owned 222,966 shares, with an additional 23,282 shares held in each of two Caraluna trusts for beneficiaries, over which they disclaim beneficial ownership.
An officer of Natera, Inc. who serves as President, Clinical Diagnostics reported multiple equity transactions in December 2025. On 12/12/2025, the officer made a charitable gift of 180 common shares, exercised 8,876 and 13,500 stock options at an exercise price of $9.59 per share, and sold 4,692 shares at an average price of $230.7575 to cover the option exercise price and tax obligations. On 12/15/2025, the officer made an additional charitable gift of 115 shares. After these transactions, the officer directly owns 126,450 common shares and holds 5,125 stock options at $9.59 per share, which are fully exercisable and expire on 04/07/2026.
Natera, Inc. reported insider activity by a company director involving both equity awards and stock sales. On 10/31/2025, the director received 132 Restricted Stock Units (RSUs) in lieu of a $23,750 quarterly cash retainer for board service, and these RSUs were fully vested at issuance, with each RSU representing one share of common stock.
Following this grant, the director held 68,761 common shares directly. On 12/12/2025, the director sold several blocks of Natera common stock: 14,372 shares at a weighted average price of $226.6174, 21,910 shares at $227.3532, 11,987 shares at $228.4858, and 150 shares at $229.095, all in multiple trades within narrow price ranges. After these transactions, the director directly owned 20,342 Natera shares.
Natera, Inc. reported an insider transaction by an officer serving as its SEC. and Chief Legal Officer. On December 4, 2025, this officer exercised stock options to acquire 6,902 shares of Natera common stock at an exercise price of $19.68 per share, converting derivative securities into common stock.
Following the transaction, the officer directly beneficially owned 208,601 shares of Natera common stock. The filing also shows 5,598 remaining stock options with a $19.68 exercise price, expiring on March 21, 2029, and notes that the option shares are fully exercisable.